Genmab A/S's (GMAB) Buy Rating Reiterated at HC Wainwright

Genmab A/S (NASDAQ:GMAB - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $37.00 price target on the stock, down from their previous price target of $50.00. HC Wainwright's target price suggests a potential upside of 96.70% from the stock's previous close. HC Wainwright also issued estimates for Genmab A/S's Q2 2025 earnings at $0.41 EPS, Q3 2025 earnings at $0.44 EPS, Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.48 EPS and FY2026 earnings at $1.72 EPS.

Other analysts also recently issued reports about the stock. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Remove Ads

Genmab A/S Price Performance

Shares of GMAB stock traded up $0.80 on Wednesday, hitting $18.81. The company's stock had a trading volume of 1,524,787 shares, compared to its average volume of 1,018,227. The stock has a market capitalization of $12.45 billion, a price-to-earnings ratio of 10.81, a P/E/G ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The firm's fifty day moving average price is $20.48 and its 200-day moving average price is $21.31.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. EverSource Wealth Advisors LLC raised its position in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its holdings in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after buying an additional 1,051 shares during the period. Barclays PLC boosted its stake in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC grew its position in Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after acquiring an additional 2,496 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.